General Information of Drug (ID: DM7WPGN)

Drug Name
4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
135566316
TTD Drug ID
DM7WPGN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
3,4-Dihydroxycinnamic Acid DMVZL26 Thrombocytopenia 3B64 Phase 4 [2]
Anti-MIF antibodies DM8EKSV Autoimmune diabetes 5A10 Phase 4 [3]
ISO-1 DMDB7KU N. A. N. A. Phase 1 [4]
COR100140 DMN0GTR Inflammation 1A00-CA43.1 Preclinical [5]
6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE DMPSOIF Discovery agent N.A. Investigative [1]
4-hydroxyphenylpyruvic acid DM0564K Discovery agent N.A. Investigative [1]
AVP-13546 DMDTONZ Autoimmune disease 4A40-4A45 Investigative [6]
AVP-13748 DMBNDYK Autoimmune disease 4A40-4A45 Investigative [6]
NAPQI DM8F5LR Autoimmune disease 4A40-4A45 Investigative [6]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Macrophage migration inhibitory factor (MIF) TT2AST1 MIF_HUMAN Inhibitor [1]

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455.
4 The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82.
5 Cortical Pty Ltd Presents MIF Antagonist Data at World Congress on Inflammation. Cortical Pty Ltd. 2005.
6 MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9.